Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2021 March;63(1) > Panminerva Medica 2021 March;63(1):7-12

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  MULTIPLE MYELOMA IN 2020: STATE OF THE ART (PART II) Freefree

Panminerva Medica 2021 March;63(1):7-12

DOI: 10.23736/S0031-0808.20.04145-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Chemotherapy-based regimens in multiple myeloma in 2020

Massimo GENTILE 1 , Fortunato MORABITO 2, Massimo MARTINO 3, Ernesto VIGNA 1, Enrica A. MARTINO 1, Francesco MENDICINO 1, Giovanni MARTINELLI 4, Claudio CERCHIONE 5

1 Unit of Hematology, Hospital of Cosenza, Cosenza, Italy; 2 Unit of Biotechnology Research, Hospital of Cosenza, Cosenza, Italy; 3 Unit of Stem Cell Transplantation and Cellular Therapies, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; 4 IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy; 5 Unit of Hematology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



Multiple myeloma (MM) represents the second-most common hematologic malignancy. In the 1980s, induction therapy with alkylating agents, such as anthracyclines and steroids, as well as high-dose chemotherapy followed by autologous stem cell transplantation were the main therapeutic approaches for MM. Since the introduction of more effective drugs, such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and histone deacetylase inhibitor, the new therapeutic algorithm allows of achieving a significantly improvement of prognosis. Numerous regimens, which differently combine these new agents, have been developed and tested in clinical trials. The results of these new regimens are reported each year. In this variegated new contest, old chemotherapeutic drugs still maintain an overriding weight, especially when beneficially combined with new drugs. Also, this is particular true in specific situations, such as extramedullary manifestations, in which tumor mass reduction becomes an urgent clinical need, or in case of chemotherapy-induced stem-cell mobilization. Moreover, melphalan represents the gold standard conditioning regimen since 2002, either alone or, possibly in the next future, in combination with busulfan. Finally, new chemotherapeutic agents with new mechanisms of action, such as melflufen, are in early experimental phase.


KEY WORDS: Multiple myeloma; Drug therapy; Therapy

top of page